JP2024526305A5 - - Google Patents
Info
- Publication number
- JP2024526305A5 JP2024526305A5 JP2024500185A JP2024500185A JP2024526305A5 JP 2024526305 A5 JP2024526305 A5 JP 2024526305A5 JP 2024500185 A JP2024500185 A JP 2024500185A JP 2024500185 A JP2024500185 A JP 2024500185A JP 2024526305 A5 JP2024526305 A5 JP 2024526305A5
- Authority
- JP
- Japan
- Prior art keywords
- represented
- following
- pharmaceutically acceptable
- stereoisomer
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163219629P | 2021-07-08 | 2021-07-08 | |
| US63/219,629 | 2021-07-08 | ||
| PCT/US2022/073517 WO2023283606A1 (en) | 2021-07-08 | 2022-07-07 | Degraders of wild-type and mutant forms of lrrk2 and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024526305A JP2024526305A (ja) | 2024-07-17 |
| JP2024526305A5 true JP2024526305A5 (cg-RX-API-DMAC7.html) | 2025-07-14 |
Family
ID=84802076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500185A Pending JP2024526305A (ja) | 2021-07-08 | 2022-07-07 | Ｌｒｒｋ２の野生型および変異体形態の分解剤ならびにその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240308982A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4367115A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024526305A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022306049A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3218951A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023283606A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024512501A (ja) | 2021-03-19 | 2024-03-19 | アルヴィナス・オペレーションズ・インコーポレイテッド | インダゾール系化合物及び関連使用方法 |
| TW202515874A (zh) | 2023-09-28 | 2025-04-16 | 美商亞文納營運公司 | 用於靶向降解富含白胺酸之重複激酶２（ｌｒｒｋ２）的基於苯并咪唑及苯并咪唑酮之ｐｒｏｔａｃ化合物 |
| WO2025201511A1 (zh) * | 2024-03-29 | 2025-10-02 | 上海京新生物医药有限公司 | 吲唑衍生物及其制备方法与应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014134772A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| US20210361774A1 (en) * | 2018-10-16 | 2021-11-25 | Dana-Farber Cancer Institute, Inc. | Degraders of wild-type and mutant forms of lrrk2 |
-
2022
- 2022-07-07 US US18/576,068 patent/US20240308982A1/en active Pending
- 2022-07-07 AU AU2022306049A patent/AU2022306049A1/en active Pending
- 2022-07-07 EP EP22838581.1A patent/EP4367115A4/en active Pending
- 2022-07-07 WO PCT/US2022/073517 patent/WO2023283606A1/en not_active Ceased
- 2022-07-07 JP JP2024500185A patent/JP2024526305A/ja active Pending
- 2022-07-07 CA CA3218951A patent/CA3218951A1/en active Pending